In a nutshell This study evaluated the safety and effectiveness of high-dose cyclophosphamide (Cytoxan) for the treatment of relapsed or unresponsive non-Hodgkin’s lymphoma (NHL). This study concluded that high-dose cyclophosphamide was safe and effective for these patients. Some background Chemotherapy regimens remain a standard treatment...
Read More
In a nutshell This study aimed to investigate if minimal residual disease negativity is useful as a prognostic factor after inotuzumab ozogamicin treatment in patients with relapsed/refractory acute lymphoblastic leukemia. This study concluded minimal residual negativity with complete remission is associated with a better...
Read More
In a nutshell This study evaluated the safety and effectiveness of gemcitabine (Gemzar) plus bendamustine (Treanda) in patients with Hodgkin lymphoma (HL) that has come back or stopped responding to treatment. This study found that this combination was well-tolerated and effective for these patients. Some background Immunotherapy remains a...
Read More
In a nutshell This study examined the effectiveness and safety of adding durvalumab (Imfinzi) to platinum-etoposide to treat patients with small-cell lung carcinoma (SCLC). The authors found that durvalumab was well-tolerated and improved survival outcomes. Some background Small cell lung carcinoma (SCLC) is a type of lung cancer that...
Read More
In a nutshell This trial is examining the safety and effectiveness of experimental drug mRNA-2752 in patients with advanced triple-negative breast cancer. The main outcome of the trial will be the number of side effects experienced by patients and response to treatment. This trial is recruiting in the United States and Israel. The details...
Read More
In a nutshell This article reviewed different treatment options for patients with melanoma. Some background Melanoma is one of the most common cancers worldwide. Treatment options for patients with melanoma depend on how extensive it is. Melanoma that remains in its original site in the skin is called localized disease. It can also...
Read More
In a nutshell This study is examining the effectiveness of biological drug sacituzumab govitecan (IMMU-132) compared to standard treatments for patients with hormone receptor-positive metastatic breast cancer. The main outcomes that will be measured are cancer responsiveness to the drug and survival of patients without the cancer growing. This trial...
Read More
In a nutshell This trial is examining the most beneficial dose of an experimental AE37 vaccine when used with biological therapy pembrolizumab (Keytruda). The main outcomes to be measured are the maximum safest dose of AE37 and objective response rate. This study is recruiting in Illinois and West Virginia, US. The details Triple-negative...
Read More
In a nutshell This study investigated survival rates in advanced non-small cell lung cancer (NSCLC) after nivolumab (Opdivo) treatment. They found that nivolumab was associated with longer survival time in patients that responded to treatment. Some background Lung cancer (LC) is one of the most common cancers worldwide. Non-small...
Read More
In a nutshell This study aimed to investigate the outcomes for patients who underwent allogeneic hematopoietic stem cell transplant after treatment with blinatumomab. This study concluded that survival was driven by the response to study treatment and by salvage status regardless of transplant status. Some...
Read More
In a nutshell This phase 1b trial is examining the effectiveness and safety of a vaccine treatment, ATP128, in the treatment of advanced colorectal cancer. The main outcome to be measured is the tumor response to the treatment and treatment toxicity. This trial is being conducted in Arizona and California, US. The details Colorectal cancer is the...
Read More
In a nutshell This study is examining the effectiveness of antibody drug tiragolumab with or without standard treatment for relapsed or unresponsive multiple myeloma or non-Hodgkin lymphoma. The main outcome would be the side effects experienced by patients 1 year after treatment. The details Both multiple myeloma (MM) and non-Hodkin lymphoma...
Read More
